Semi-annual Report for 2026
Filed with SSE · · 166 pages · Chinese
GuiZhou SanLi Pharmaceutical Co., Ltd. on 6ix
Earlier from GuiZhou SanLi Pharmaceutical
- Announcement on Reply to the Shanghai Stock Exchange's Information Disclosure Supervisory Inquiry Letter on the Company's 2025 Annual Report
- Announcement on Implementation of Repurchase and Cancellation of Restricted Shares under the Equity Incentive Plan
- Announcement on Expected Decrease in Semi-annual Performance for 2026
- Announcement on Pledging Partial Shares of Person Acting in Concert of Controlling Shareholder
- Announcement on Implementation of Dividend Distribution for 2025
Later from GuiZhou SanLi Pharmaceutical
- Announcement on Abnormal Fluctuations in Stock Trading
- (603439)"GUIZHOU SANLI PHARMACEUTICAL CO., LTD."Announcement on Release of Pledge and Pledge of Certain Shares Held by Controlling Shareholder
- (603439)"GUIZHOU SANLI PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 27th Meeting of the 4th Board of Directors
- (603439)"GUIZHOU SANLI PHARMACEUTICAL CO., LTD."Report for Q3 2026
- (603439)"GUIZHOU SANLI PHARMACEUTICAL CO., LTD."Announcement on Renewal of the Acting-in-Concert Agreement by the Controlling Shareholder and Actual Controller
Follow GuiZhou SanLi Pharmaceutical into a list and get an email when it puts out news.
Follow GuiZhou SanLi Pharmaceutical